Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC101 TIL in Patients With Brain Glioma
NCT04943913Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- May 2021
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nolgileucel in glioma, sponsored by Juncell Therapeutics. Primary endpoints: Adverse Events at 1 month, Objective Response Rate up to 36 months and 4 more. Started May 2021; status: recruiting.
02
Drugs
nolgileucel
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04943913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943913.